First patient treated in phase 2 obesity trial of GLY-200 polymer
Glyscend Therapeutics has initiated a Phase 2 clinical trial of its lead candidate, GLY-200, as a novel oral treatment for obesity....
top of page
Browse by category
Search
Metabolic benefits of oral polymer-based duodenal exclusion therapy
Glyscend Therapeutics has presented preclinical study results at EASD 2021 evaluating the metabolic effects of once-daily oral therapy in...
Browse by tag
bottom of page